Home LiteratureArticle Details
PMID: 17878955 Published · epublish English Journal Article Research Support, Non-U.S. Gov't

HLA alleles associated with slow progression to AIDS truly prefer to present HIV-1 p24.

PloS one ·Vol. 2 ·No. 9 ·2007-09-19 ·Pages e920

Borghans JA, Mølgaard A, de Boer RJ, Keşmir C

Abstract

The mechanism behind the association between human leukocyte antigen (HLA) molecules and the rate of HIV-1 disease progression is still poorly understood. Recent data suggest that "protective" HLA molecules, i.e. those associated with a low HIV-1 viral load and relatively slow disease progression, tend to present epitopes from the Gag capsid protein. Although this suggests that preferential targeting of Gag delays disease progression, the apparent preference for Gag could also be a side-effect of the relatively high immunogenicity of the protein. To separate cause and effect, we predicted HIV-1 epitopes from the whole genome of HIV-1, and found that protective HLA alleles have a true preference for the p24 Gag protein, while non-protective HLA alleles preferentially target HIV-1 Nef. In line with this, we found a significant negative correlation between the predicted affinity of the best-binding p24 epitopes and the relative hazard of HIV-1 disease progression for a large number of HLA molecules. When the epitopes targeted by protective HLA alleles were mapped to the known p24 structure, we found that mutations in these epitopes are likely to disturb the p24 dimer structure, which is expected to severely reduce the fitness of the virus. Our results suggest that the intrinsic preference of different HLA molecules to present p24 peptides explains why some HLA molecules are more protective than others.

MeSH Terms
Alleles Disease Progression HIV Core Protein p24/chemistry,metabolism HIV Infections/pathology HIV-1 HLA Antigens/genetics Humans Models, Molecular
Chemicals
HIV Core Protein p24 HLA Antigens
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Borghans José A M
Theoretical Biology/Bioinformatics, Utrecht University, Utrecht, The Netherlands.
Mølgaard Anne
de Boer Rob J
Keşmir Can
References (57)
57 references, click to expand
  1. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method.
    BMC Bioinformatics. 2005;6:132 PMID: 15927070
  2. High responsiveness of HLA-B57-restricted Gag-specific CD8+ T cells in vitro may contribute to the protective effect of HLA-B57 in HIV-infection.
    Eur J Immunol. 2005 Jan;35(1):150-8 PMID: 15593302
  3. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes.
    Nat Immunol. 2006 Feb;7(2):173-8 PMID: 16369537
  4. Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control.
    J Virol. 2006 Mar;80(6):3122-5 PMID: 16501126
  5. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1.
    J Virol. 2006 Apr;80(7):3617-23 PMID: 16537629
  6. Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations.
    J Exp Med. 2006 May 15;203(5):1357-69 PMID: 16682496
  7. HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1.
    PLoS Med. 2006 Oct;3(10):e403 PMID: 17076553
  8. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load.
    Nat Med. 2007 Jan;13(1):46-53 PMID: 17173051
  9. Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression.
    J Immunol. 2007 Mar 1;178(5):2746-54 PMID: 17312117
  10. Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes.
    J Virol. 2007 Apr;81(7):3667-72 PMID: 17251285
  11. Effective T-cell responses select human immunodeficiency virus mutants and slow disease progression.
    J Virol. 2007 Jun;81(12):6742-51 PMID: 17409157
  12. A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection.
    J Immunol. 2007 Jun 15;178(12):7890-901 PMID: 17548627
  13. Recognition of a defined region within p24 gag by CD8+ T cells during primary human immunodeficiency virus type 1 infection in individuals expressing protective HLA class I alleles.
    J Virol. 2007 Jul;81(14):7725-31 PMID: 17494064
  14. Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B*5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infection.
    J Virol. 2007 Aug;81(15):8346-51 PMID: 17507468
  15. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS.
    N Engl J Med. 2001 May 31;344(22):1668-75 PMID: 11386265
  16. The Protein Data Bank.
    Nucleic Acids Res. 2000 Jan 1;28(1):235-42 PMID: 10592235
  17. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism.
    Immunogenetics. 1999 Nov;50(3-4):201-12 PMID: 10602880
  18. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi.
    J Immunol. 2000 Feb 1;164(3):1602-11 PMID: 10640781
  19. Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain.
    J Virol. 2000 Jun;74(12):5395-402 PMID: 10823843
  20. Timing the ancestor of the HIV-1 pandemic strains.
    Science. 2000 Jun 9;288(5472):1789-96 PMID: 10846155
  21. Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma.
    J Virol. 2002 Mar;76(5):2298-305 PMID: 11836408
  22. Cross-reactive cytotoxic T lymphocytes against a HIV-1 p24 epitope in slow progressors with B*57.
    AIDS. 2002 May 3;16(7):961-72 PMID: 11953462
  23. Prediction of proteasome cleavage motifs by neural networks.
    Protein Eng. 2002 Apr;15(4):287-96 PMID: 11983929
  24. Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design?
    J Virol. 2002 Jun;76(11):5435-51 PMID: 11991972
  25. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level.
    Science. 2002 May 24;296(5572):1439-43 PMID: 12029127
  26. Nucleic acid-independent retrovirus assembly can be driven by dimerization.
    J Virol. 2002 Nov;76(22):11177-85 PMID: 12388677
  27. Inverse correlation between memory Gag-specific cytotoxic T lymphocytes and viral replication in human immunodeficiency virus-infected children.
    J Infect Dis. 2002 Dec 1;186(11):1589-96 PMID: 12447734
  28. Association between virus-specific T-cell responses and plasma viral load in human immunodeficiency virus type 1 subtype C infection.
    J Virol. 2003 Jan;77(2):882-90 PMID: 12502804
  29. The influence of HLA genotype on AIDS.
    Annu Rev Med. 2003;54:535-51 PMID: 12525683
  30. Functional surfaces of the human immunodeficiency virus type 1 capsid protein.
    J Virol. 2003 May;77(9):5439-50 PMID: 12692245
  31. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations.
    Protein Sci. 2003 May;12(5):1007-17 PMID: 12717023
  32. Advantage of rare HLA supertype in HIV disease progression.
    Nat Med. 2003 Jul;9(7):928-35 PMID: 12819779
  33. Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors.
    J Immunol. 2003 Aug 15;171(4):1741-9 PMID: 12902473
  34. Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach.
    Tissue Antigens. 2003 Nov;62(5):378-84 PMID: 14617044
  35. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection.
    AIDS. 2003 Dec 5;17(18):2581-91 PMID: 14685052
  36. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities.
    J Virol. 2004 Mar;78(5):2187-200 PMID: 14963115
  37. HIV evolution: CTL escape mutation and reversion after transmission.
    Nat Med. 2004 Mar;10(3):282-9 PMID: 14770175
  38. Reversion of CTL escape-variant immunodeficiency viruses in vivo.
    Nat Med. 2004 Mar;10(3):275-81 PMID: 14966520
  39. Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load.
    J Virol. 2004 Apr;78(7):3233-43 PMID: 15016844
  40. Definition of supertypes for HLA molecules using clustering of specificity matrices.
    Immunogenetics. 2004 Mar;55(12):797-810 PMID: 14963618
  41. HIV-1 Nef is preferentially recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic diversity.
    AIDS. 2004 Jul 2;18(10):1383-92 PMID: 15199314
  42. The stoichiometry of Gag protein in HIV-1.
    Nat Struct Mol Biol. 2004 Jul;11(7):672-5 PMID: 15208690
  43. Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27-positive long-term-nonprogressing child.
    J Virol. 2004 Aug;78(16):8927-30 PMID: 15280502
  44. Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDS.
    Proc Natl Acad Sci U S A. 2004 Aug 17;101(33):12266-70 PMID: 15302942
  45. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides.
    Nature. 1988 Dec 1;336(6198):484-7 PMID: 2461519
  46. Sequence logos: a new way to display consensus sequences.
    Nucleic Acids Res. 1990 Oct 25;18(20):6097-100 PMID: 2172928
  47. Crystal structure of dimeric HIV-1 capsid protein.
    Nat Struct Biol. 1996 Sep;3(9):763-70 PMID: 8784350
  48. Identification of a novel HLA-B*2705-restricted cytotoxic T-lymphocyte epitope within a conserved region of HIV-1 Nef.
    AIDS. 1997 Mar 15;11(4):536-8 PMID: 9084804
  49. Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein.
    Science. 1997 Oct 31;278(5339):849-53 PMID: 9346481
  50. Analysis of the assembly function of the human immunodeficiency virus type 1 gag protein nucleocapsid domain.
    J Virol. 1998 Mar;72(3):1782-9 PMID: 9499028
  51. Characterization of HLA-B57-restricted human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T lymphocyte responses.
    J Gen Virol. 1998 Sep;79 ( Pt 9):2191-201 PMID: 9747728
  52. Conserved CTL epitopes shared between HIV-infected human long-term survivors and chimpanzees.
    J Immunol. 1999 Feb 15;162(4):2308-14 PMID: 9973508
  53. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage.
    Science. 1999 Mar 12;283(5408):1748-52 PMID: 10073943
  54. Molecular and functional analysis of a conserved CTL epitope in HIV-1 p24 recognized from a long-term nonprogressor: constraints on immune escape associated with targeting a sequence essential for viral replication.
    J Immunol. 1999 Mar 15;162(6):3727-34 PMID: 10092836
  55. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices.
    Nat Biotechnol. 1999 Jun;17(6):555-61 PMID: 10385319
  56. Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope.
    J Virol. 2004 Dec;78(24):13901-10 PMID: 15564498
  57. HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load.
    J Virol. 2005 Aug;79(16):10218-25 PMID: 16051815
Article Info
Journal
PloS one
Abbr.
PLoS One
ISSN
1932-6203
Published
2007-09-19
Epub
2007-00-19
Pages
e920
Language
English
Region
United States
NLM ID
101285081
PMCID
PMC1976389
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]